Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 12, 2007

Chromos and Genitope Sign Cell Line Engineering Contract

  • Chromos Molecular Systems entered into a cell line engineering service agreement with Genitope to develop a cell line using Chromos’ ACE system for potential use in the clinical and commercial manufacture of a biopharmaceutical product.

    Specifically, Chromos will engineer cell lines for the expression of a Mab for Genitope. According to Chromos, recent data generated by one of its partners has shown that cell lines engineered using ACE are capable of achieving Mab yields of greater than 4 g/L in a nonoptimized bioreactor system, a four-fold improvement over the partner’s original cell line.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »